Literature DB >> 25213129

Increased rho kinase activity in temporal artery biopsies from patients with giant cell arteritis.

Lindsay Lally1, Alessandra Pernis2, Navneet Narula3, Wei-Ti Huang3, Robert Spiera2.   

Abstract

OBJECTIVE: Aberrant rho kinase (ROCK) activity is implicated in the pathogenesis of several vascular diseases and is associated with Th17 differentiation. Th17 immune response is recognized in the pathogenesis of GCA. The aim of this study was to assess ROCK activity in GCA.
METHODS: All patients who underwent temporal artery biopsy (TAB) at a tertiary care centre over 5 years were identified and charts reviewed. Subjects were categorized into three groups: TAB-positive GCA, TAB-negative GCA and age- and sex-matched controls. TABs were stained for phosphorylated ezrin/radixin/moesin (pERM), a surrogate of ROCK activity, and reviewed by a pathologist blinded to clinical status. Three areas were scored for staining intensity on a scale of 0-2, with a maximum possible score of 6.
RESULTS: Nineteen subjects with TAB-positive GCA, 17 with TAB-negative GCA and 18 controls were analysed. Compared with controls, GCA subjects with either positive or negative TABs had significantly higher pERM intensity scores (P = 0.0109). Adjusting for diabetes, hypertension, prednisone and statin use, GCA subjects still had higher pERM scores [odds ratio 7.3 (95% CI 1.9, 25.9), P = 0.0046]. The high pERM score had a sensitivity of 90% and a negative predictive value of 91% for the diagnosis of GCA in those with a negative TAB, compared with 51% sensitivity for histopathology alone.
CONCLUSION: Subjects with GCA had more intense pERM staining in TAB specimens compared with age- and sex-matched controls, regardless of whether TAB was positive or negative by routine histopathology, suggesting increased ROCK activity in GCA. The ROCK pathway warrants further investigation in GCA, as it may have diagnostic significance in enhancing the sensitivity of TAB.
© The Author 2014. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  giant cell arteritis; rho-associated kinases; vasculitis

Mesh:

Substances:

Year:  2014        PMID: 25213129      PMCID: PMC4334685          DOI: 10.1093/rheumatology/keu364

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  20 in total

1.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis.

Authors:  G G Hunder; D A Bloch; B A Michel; M B Stevens; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt; J T Lie
Journal:  Arthritis Rheum       Date:  1990-08

2.  Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis.

Authors:  Georgina Espígol-Frigolé; Marc Corbera-Bellalta; Ester Planas-Rigol; Ester Lozano; Marta Segarra; Ana García-Martínez; Sergio Prieto-González; José Hernández-Rodríguez; Josep M Grau; Mahboob U Rahman; Maria C Cid
Journal:  Ann Rheum Dis       Date:  2012-09-19       Impact factor: 19.103

3.  Meta-analysis: test performance of ultrasonography for giant-cell arteritis.

Authors:  Fotini B Karassa; Miltiadis I Matsagas; Wolfgang A Schmidt; John P A Ioannidis
Journal:  Ann Intern Med       Date:  2005-03-01       Impact factor: 25.391

4.  Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy.

Authors:  M A Gonzalez-Gay; C Garcia-Porrua; J Llorca; C Gonzalez-Louzao; P Rodriguez-Ledo
Journal:  Semin Arthritis Rheum       Date:  2001-02       Impact factor: 5.532

5.  Phosphorylated ERM is responsible for increased T cell polarization, adhesion, and migration in patients with systemic lupus erythematosus.

Authors:  Yansong Li; Tatsuhiro Harada; Yuang-Taung Juang; Vasileios C Kyttaris; Ying Wang; Michael Zidanic; Kenneth Tung; George C Tsokos
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

Review 6.  Immunopathways in giant cell arteritis and polymyalgia rheumatica.

Authors:  Cornelia M Weyand; Wei Ma-Krupa; Jörg J Goronzy
Journal:  Autoimmun Rev       Date:  2004-01       Impact factor: 9.754

7.  Initiation of glucocorticoid therapy: before or after temporal artery biopsy?

Authors:  Brian R Younge; Briggs E Cook; George B Bartley; David O Hodge; Gene G Hunder
Journal:  Mayo Clin Proc       Date:  2004-04       Impact factor: 7.616

8.  Quantification of the role of temporal artery biopsy in diagnosing clinically suspected giant cell arteritis.

Authors:  D Varma; D O'Neill
Journal:  Eye (Lond)       Date:  2004-04       Impact factor: 3.775

Review 9.  Polymyalgia rheumatica and giant-cell arteritis.

Authors:  Carlo Salvarani; Fabrizio Cantini; Gene G Hunder
Journal:  Lancet       Date:  2008-07-19       Impact factor: 79.321

10.  Rho-kinase phosphorylates COOH-terminal threonines of ezrin/radixin/moesin (ERM) proteins and regulates their head-to-tail association.

Authors:  T Matsui; M Maeda; Y Doi; S Yonemura; M Amano; K Kaibuchi; S Tsukita; S Tsukita
Journal:  J Cell Biol       Date:  1998-02-09       Impact factor: 10.539

View more
  4 in total

Review 1.  ROCK2, a critical regulator of immune modulation and fibrosis has emerged as a therapeutic target in chronic graft-versus-host disease.

Authors:  Alexandra Zanin-Zhorov; Bruce R Blazar
Journal:  Clin Immunol       Date:  2021-08-14       Impact factor: 10.190

Review 2.  Giant Cell Arteritis: Beyond Corticosteroids.

Authors:  Lauren Steel; Asad Khan; Bhaskar Dasgupta
Journal:  Drugs Aging       Date:  2015-08       Impact factor: 3.923

Review 3.  ROCK as a therapeutic target for ischemic stroke.

Authors:  Nikola Sladojevic; Brian Yu; James K Liao
Journal:  Expert Rev Neurother       Date:  2017-10-30       Impact factor: 4.618

Review 4.  The RhoA-ROCK pathway in the regulation of T and B cell responses.

Authors:  Edd Ricker; Luvana Chowdhury; Woelsung Yi; Alessandra B Pernis
Journal:  F1000Res       Date:  2016-09-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.